Latest News

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with James Berry, MD, MPH; and Jinsy Andrews, MD, MSc. [LISTEN TIME: 28 minutes]

Beatrice Yang, MD, lead specialist for patient insights at Lundbeck, discussed how incorporating patient and caregiver feedback helped shape the design of a phase 3 multiple system atrophy trial to make participation more practical and patient-centered.

Eva Mistry, MD, an associate professor of neurology at the University of Cincinnati, discusses the mechanism, rationale, and clinical data supporting SCP776, a first-in-class IGF-1-based cerebroprotective therapy for acute ischemic stroke.

The phase 3 FORTIFY trial of BBP-418 met its primary and key secondary interim analysis end points and demonstrated a safety profile consistent with prior studies in patients with LGMD2I/R9.

Liche Zhou, MD, of the department of neurology at Jiang University School of Medicine, provided commentary on new phase 1 data on an iPSC-targeted cell therapy presented at the 2025 MDS Congress.

New trial results reveal alixorexton's significant efficacy in treating narcolepsy type 2, marking a potential breakthrough in sleep medicine.

Findings from a second phase 3 trial, dubbed FENhance 1, assessing fenebrutinib in patients with relapsing multiple sclerosis are anticipated by the first half of 2026.

The vice president and Asset Head of Rare and Ultra-Rare Diseases at UCB provided clinical perspectives on the FDA approval of Kygevvi, the first marketed treatment specific for patients with thymidine kinase 2 deficiency (Tk2d).

Jupiter Neurosciences advances Parkinson treatment with FDA clearance for JOTROL's phase 2a trial, showcasing promising safety and bioavailability results.

A genetic counselor-only clinic enhances access to genetic testing in pediatric neurology, proving efficient and effective for timely precision diagnostics.

Caregivers share insights on discussing social determinants of health in pediatric clinics, revealing preferences for surveys over in-person conversations.

A study reveals the intricate decision-making process caregivers face when considering gene therapy for Duchenne muscular dystrophy, emphasizing shared input and personal experiences.

Catch up on any of the neurology news headlines you may have missed in October 2025, compiled into 1 place by the NeurologyLive® team.